 |
|
 |
 |
|||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||
| Kollodis Enters into Distribution Agreement for MAPTrix® ECM with Cambridge Bioscience | |||||||||||||||||||||||||||||
| (MALDEN, MA) January 06, 2010- Kollodis BioSciences, Inc. announced today that it has entered into an Exclusive Distribution Agreement with Cambridge Bioscience Ltd. for the distribution of Kollodis BioSciences, Inc.'s MAPTrix® ECM line of products for cell culture and related applications. The exclusive agreement provides Cambridge Bioscience with the rights to distribute Kollodis’ cell culture products in the United Kingdom and Republic of Ireland. Cambridge Bioscience is a well established marketing partner for life science technology companies wishing to build their business in the European markets. The initial term of the appointment is two years which may be extended. Dr. Louis M. Scarmoutzos, President & CEO of Kollodis BioSciences, Inc., stated, "MAPTrix® is an exciting business opportunity providing a unique offering that can be of great value for its clients and customers in academics and in the pharmaceutical and life sciences industries. The appointment of Cambridge Bioscience as our distributor will provide us with an extended reach into the important UK and Ireland markets." Mike Kerins, Managing Director at Cambridge Bioscience commented, “We are delighted to be working with Kollodis on the commercialization of their highly innovative MAPTrix® technology. We see wide application for this technology in the areas of stem cell research and tissue engineering. Among the Mussel Adhesive Protein based matrix (MAPTrix®) ECM line of products are reagents with genetically incorporated bioactive peptides (recognition peptides) that mimic the extracellular matrix (ECM) activity of collagen, fibronectin, laminin, and vitronectin proteins. The bioactive peptide mimics the extracellular matrix (ECM) protein and provides for cell attachment, spreading and growth. The mussel adhesive protein confers biocompatible adhesion to a wide variety of surfaces. A MAPTrix® surface coating application promotes cell plating efficiency, improves morphology, and enhances cell proliferation under serum-free conditions in primary cell cultures such as hepatocytes or neural cells. About Kollodis BioSciences, Inc. Kollodis BioSciences, Inc. has successfully developed a proprietary recombinant protein expression system for the large scale production of various mussel adhesive proteins (MAP). Kollodis is developing MAP-based smart biomaterials for biotech, medical and industrial applications. The Company's proprietary and patented MAPTrix® platform technology recombinantly incorporates bioactive peptides into a mussel adhesive protein (MAP) for cell culture and related applications. Additional information is available on the Company's website at www.kollodis.com. About Cambridge Bioscience Limited Cambridge Bioscience Ltd. is a leading distributor in the U.K. and Ireland, providing products for life science research. One of the longest established companies serving this market, Cambridge Bioscience has built a comprehensive product portfolio representing some of the world’s most innovative suppliers. With over 22 years of experience, the expertise and knowledge within the company is used in identifying and fulfilling the requirements of the research community. Additional information is available on the Company's website at www.bioscience.co.uk. |
|||||||||||||||||||||||||||||
